Amedeo Smart

Free Medical Literature Service

 

Amedeo

Obstructive Lung Diseases
  Free Subscription

Articles published in
Eur Respir J
    November 2025
  1. HAKANSSON KEJ, Hansen S, Soendergaard MB, von Bulow A, et al
    Long-term efficacy but rare sustained remission: Individual-level five-year stability in anti-IL5/Ralpha biologic therapy response for severe asthma.
    Eur Respir J. 2025 Nov 27:2500926. doi: 10.1183/13993003.00926-2025.
    >> Share

  2. HALPIN DM, Masekela R, Vogelmeier CF, Ozoh OB, et al
    Addressing the global challenges of COPD and asthma: a shared vision from the global initiative for chronic obstructive pulmonary disease (GOLD) and the global initiative for asthma (GINA).
    Eur Respir J. 2025 Nov 6:2502244. doi: 10.1183/13993003.02244-2025.
    >> Share

  3. SIBILA O, Perea L, Aliberti S
    Emerging therapies in bronchiectasis.
    Eur Respir J. 2025 Nov 6:2501309. doi: 10.1183/13993003.01309-2025.
    >> Share

  4. HANSEN S, von Bulow A, Cooper A, Sandin P, et al
    Mortality in Severe Asthma - results from the NORDSTAR cohort.
    Eur Respir J. 2025 Nov 6:2501289. doi: 10.1183/13993003.01289-2025.
    >> Share

  5. CUTTING CC, Rose JA, Tukpah AC, Wada N, et al
    Interstitial lung abnormalities, coronary heart disease and mortality.
    Eur Respir J. 2025;66:2402286.
    >> Share

  6. DUIVERMAN ML, Ribeiro C, Tonia T, Hazenberg A, et al
    European Respiratory Society clinical practice guideline on telemedicine in home mechanical ventilation.
    Eur Respir J. 2025;66:2500094.
    >> Share

    October 2025
  7. HOWELL I, Mahdi M, Mahmood HR, Bermejo-Sanchez L, et al
    Exhaled nitric oxide (FeNO) and the response to prednisolone for asthma attacks in patients treated with anti-IL5/5Ralpha therapy: a prospective observational study.
    Eur Respir J. 2025 Oct 9:2501229. doi: 10.1183/13993003.01229-2025.
    >> Share

  8. LEUNG C, Leung JM, Sin DD
    Reply to: Decoding the eosinophil connection: implications for precision treatment of emphysematous in COPD.
    Eur Respir J. 2025;66:2501584.
    >> Share

  9. SUN W
    Decoding the eosinophil connection: implications for precision treatment of emphysematous in COPD.
    Eur Respir J. 2025;66:2501403.
    >> Share

  10. RICHARDSON H, Alferes De Lima Headley D, Clarke C, Veluchamy A, et al
    The effect of different inhaled corticosteroid and long-acting bronchodilator combinations on the airway microbiome in patients with severe COPD: a randomised trial (MUSIC).
    Eur Respir J. 2025;66:2500287.
    >> Share

  11. ZHU Z, Liu C, Ober C, Camargo CA Jr, et al
    Gene-environment interaction at 17q12-q21 locus and its role in asthma pathogenesis.
    Eur Respir J. 2025;66:2501232.
    >> Share

  12. ANNESI-MAESANO I, Bayram H, Cecchi L, Croft D, et al
    Natural disasters and respiratory health.
    Eur Respir J. 2025;66:2402563.
    >> Share

    September 2025
  13. CHALMERS JD, Haworth CS, Flume P, Long MB, et al
    European Respiratory Society Clinical Practice Guideline for the Management of Adult Bronchiectasis.
    Eur Respir J. 2025 Sep 28:2501126. doi: 10.1183/13993003.01126-2025.
    >> Share

  14. DAVIES TJ, Pavord ID
    Lymphoma in patients with asthma treated with dupilumab: much ado about nothing?
    Eur Respir J. 2025;66:2501321.
    >> Share


  15. ERJ Podcast September 2025: Neutrophil-derived biomarkers in bronchiectasis.
    Eur Respir J. 2025;66:25E6603.
    >> Share

  16. RASTODER E, Sivapalan P, Hedsund C, Kamstrup P, et al
    Pulmonary pressure increases during acute exacerbation in COPD and clinical outcome.
    Eur Respir J. 2025;66:2500169.
    >> Share

    August 2025
  17. LEE B, Wong E, Tan T, Rupani H, et al
    Pregnancy, asthma and exacerbations: a population-based cohort.
    Eur Respir J. 2025 Aug 28:2501327. doi: 10.1183/13993003.01327-2025.
    >> Share

  18. BACOPANOS E, Forrester DL, Girdler E, Gonnelli F, et al
    The increasing burden of bronchiectasis in the United Kingdom.
    Eur Respir J. 2025 Aug 28:2500909. doi: 10.1183/13993003.00909-2025.
    >> Share

  19. NARAYANA JK, Koo Wei Ling Y, Mac Aogain M, Chotirmall SH, et al
    Characterizing research trends in bronchiectasis through AI-powered analytics.
    Eur Respir J. 2025 Aug 28:2500894. doi: 10.1183/13993003.00894-2025.
    >> Share

  20. WILKINSON TMA, Akuthota P
    CompEx Asthma: is it time for a change in clinical trials?
    Eur Respir J. 2025 Aug 21:2500470. doi: 10.1183/13993003.00470-2025.
    >> Share

  21. MANGALICK K, Segal LN
    Just like good wine, European bronchiectasis deserves regional denominations.
    Eur Respir J. 2025;66:2501020.
    >> Share

    July 2025
  22. CHALMERS JD, Mall MA, Nielsen KG, Chang AB, et al
    Neutrophil-derived biomarkers in bronchiectasis: identifying a common therapeutic target.
    Eur Respir J. 2025 Jul 10:2500081. doi: 10.1183/13993003.00081-2025.
    >> Share

  23. LIU KY, Sie JJ, Gao Y, Lo YL, et al
    Functional sequence variants of intergenic long non-coding RNA on Chromosome 17q21 are associated with asthma.
    Eur Respir J. 2025 Jul 3:2500847. doi: 10.1183/13993003.00847-2025.
    >> Share

  24. KHALAILI L, Aliberti S, Viligorska K, Blasi F, et al
    Greater disease severity in adults with paediatric-onset versus adult-onset bronchiectasis: a multicenter EMBARC registry study.
    Eur Respir J. 2025 Jul 3:2500665. doi: 10.1183/13993003.00665-2025.
    >> Share

  25. SINGH D, Guller P, Reid F, Doffman S, et al
    A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4.
    Eur Respir J. 2025;66:2402231.
    >> Share

  26. MENON L, Blakey J, Ramakrishnan S
    Type 2 inflammatory biomarkers in asthma and COPD: what we think we know.
    Eur Respir J. 2025;66:2500685.
    >> Share

  27. CELIS-PRECIADO C, Lemaire-Paquette S, Lachapelle P, Couillard S, et al
    Reply to: Type 2 inflammatory biomarkers in asthma and COPD: what we think we know.
    Eur Respir J. 2025;66:2500949.
    >> Share

  28. DELGADO-ORTIZ L, Buekers J, Chynkiamis N, Demeyer H, et al
    How do people with COPD walk? A European study on digitally measured real-world gait.
    Eur Respir J. 2025;66:2402303.
    >> Share

    June 2025
  29. SHENG-KAI MA K, Brumbaugh B, Saff RR, Phipatanakul W, et al
    Dupilumab and lymphoma risk among patients with asthma: a population-based cohort study.
    Eur Respir J. 2025 Jun 19:2500139. doi: 10.1183/13993003.00139-2025.
    >> Share

    May 2025
  30. THNG KX, Tiew PY, Mac Aogain M, Narayana JK, et al
    Sputum metagenomics in bronchiectasis reveals pan-European variation: an EMBARC-BRIDGE study.
    Eur Respir J. 2025 May 22:2500054. doi: 10.1183/13993003.00054-2025.
    >> Share

  31. WU SM, Chen KY, Chuang HC, Ho SC, et al
    Particulate matter-related ITIH4 deficiency is associated with an emphysema phenotype of chronic obstructive pulmonary disease through JNK-dependent and JNK-independent signaling.
    Eur Respir J. 2025 May 22:2401610. doi: 10.1183/13993003.01610-2024.
    >> Share

  32. CARLIER FM, Detry B, Ambroise J, Heddebaut N, et al
    Impaired IgA Mucosal Immunity Following Lung Transplantation: A Potential Trigger for Bronchiolitis Obliterans Syndrome.
    Eur Respir J. 2025 May 22:2402212. doi: 10.1183/13993003.02212-2024.
    >> Share

  33. GIRAULT A, Le A, Gonsard A, Abou Taam R, et al
    ChatGPT and Other Large Language Models for Parents' Questions About Childhood Asthma: A Comparative Study.
    Eur Respir J. 2025 May 15:2500254. doi: 10.1183/13993003.00254-2025.
    >> Share

  34. LEUNG C, Park HY, Li X, Koelwyn GJ, et al
    Transcriptomic profiling of the airway epithelium in COPD links airway eosinophilia to type 2 inflammation and corticosteroid response.
    Eur Respir J. 2025;65:2401875.
    >> Share

  35. DARIE AM, Grize L, Jahn K, Salina A, et al
    Preventing oxygen desaturation during bronchoscopy in COPD patients using high-flow oxygen versus standard management: the randomised controlled PROSA 2 trial.
    Eur Respir J. 2025;65:2401586.
    >> Share

  36. BUSSE WW, O'Byrne PM
    Are systemic corticosteroids needed for all asthma exacerbations?
    Eur Respir J. 2025;65:2500370.
    >> Share

    April 2025
  37. SHI MX, Guo SJ, Yue JQ, Zhang XX, et al
    Blood eosinophil counts, airway infections and inhaled antibiotic treatment in bronchiectasis.
    Eur Respir J. 2025 Apr 23:2500518. doi: 10.1183/13993003.00518-2025.
    >> Share

  38. YANG F, Bossios A
    Who really responds to asthma biologics? The clue lies in the journey before treatment.
    Eur Respir J. 2025;65:2500044.
    >> Share

  39. SAFERALI A, Wienecke AN, Xu Z, Liu T, et al
    Characterisation of a COPD-associated nephronectin (NPNT) functional splicing genetic variant in human lung tissue via long-read sequencing.
    Eur Respir J. 2025;65:2401407.
    >> Share


  40. "Epigenomic partitioning of a polygenic risk score for asthma reveals distinct genetically driven disease pathways." B. Stikker, L. Trap, B. Sedaghati-Khayat, et al. Eur Respir J 2024; 64: 2302059.
    Eur Respir J. 2025;65:2352059.
    >> Share

  41. KOURID MI, Couillard S
    Lunsekimig's bispecific targeting of IL-13 and TSLP in asthma: dual targets for synergistic effects?
    Eur Respir J. 2025;65:2500153.
    >> Share

  42. HAMADA Y, Thomas D, Gibson PG
    Reply to: Critique of logistic regression in analysing treatment response in severe eosinophilic asthma.
    Eur Respir J. 2025;65:2500516.
    >> Share


  43. "Advancing patient-centred care in measuring response to biologics in severe asthma." Vanesa Bellou. Eur Respir J 2025; 65: 2402113.
    Eur Respir J. 2025;65:2452113.
    >> Share

  44. TAKEFUJI Y
    Critique of logistic regression in analysing treatment response in severe eosinophilic asthma.
    Eur Respir J. 2025;65:2500423.
    >> Share

    March 2025
  45. NEW BJ, Chalmers JD
    Unbreak my heart: macrolide cardiovascular benefits and safety in bronchiectasis.
    Eur Respir J. 2025;65:2500045.
    >> Share

  46. BELLOU V
    Advancing patient-centred care in measuring response to biologics in severe asthma.
    Eur Respir J. 2025;65:2402113.
    >> Share

    February 2025
  47. BOURDIN A, Nogue E, Matzner-Lober E, Malafaye N, et al
    What can lockdowns tell us about the underlying causes of asthma exacerbations? A retrospective cohort study.
    Eur Respir J. 2025 Feb 27:2402264. doi: 10.1183/13993003.02264-2024.
    >> Share

  48. CELIS-PRECIADO C, Leclerc S, Duval M, Cliche DO, et al
    Phenotyping the Responses to Systemic Corticosteroids in the Management of Asthma Attacks (PRISMA).
    Eur Respir J. 2025 Feb 13:2402391. doi: 10.1183/13993003.02391-2024.
    >> Share

  49. SINGH D, Stockley R, Anzueto A, Agusti A, et al
    GOLD Science Committee recommendations for the use of pre- and post-bronchodilator spirometry for the diagnosis of COPD.
    Eur Respir J. 2025;65:2401603.
    >> Share

  50. WADE RC, Martinez FJ, Criner GJ, Tombs L, et al
    ECG-based risk factors for adverse cardiopulmonary events and treatment outcomes in COPD.
    Eur Respir J. 2025;65:2400171.
    >> Share

  51. MAILHOT-LAROUCHE S, Busby J, Couillard S
    Response and remission in asthma with tezepelumab: overlapping concepts informing on type-2 inflammatory-dependent treatment effects.
    Eur Respir J. 2025;65:2402057.
    >> Share

  52. MARTIN N, Wechsler ME, Brightling CE
    Reply to: Response and remission in asthma with tezepelumab: overlapping concepts informing on type-2 inflammatory-dependent treatment effects.
    Eur Respir J. 2025;65:2402434.
    >> Share

    January 2025
  53. DEITEREN A, Krupka E, Bontinck L, Imberdis K, et al
    A proof-of-mechanism trial in asthma with lunsekimig, a bispecific nanobody(R) molecule.
    Eur Respir J. 2025 Jan 30:2401461. doi: 10.1183/13993003.01461-2024.
    >> Share

  54. SOENDERGAARD MB, Hjortdahl F, Hansen S, Bjerrum AS, et al
    Pre-biologic disease trajectories are associated with morbidity burden and biologic treatment response in severe asthma.
    Eur Respir J. 2025 Jan 9:2401497. doi: 10.1183/13993003.01497-2024.
    >> Share

  55. ARBIV OA, Quon BS
    Disarming the cavalry: targeting neutrophils to limit collateral damage in non-CF bronchiectasis.
    Eur Respir J. 2025;65:2401804.
    >> Share

  56. KHEDOE PPSJ, van 't Wout EFA
    Buddy, bystander or betrayer: B cells in lymphoid aggregates in AATD emphysema.
    Eur Respir J. 2025;65:2402163.
    >> Share

  57. NOLASCO S, Mukherjee M, Nair P
    Trajectories of responses to mepolizumab in severe asthma.
    Eur Respir J. 2025;65:2402023.
    >> Share


  58. ERJ Podcast January 2025: Treatment response to mepolizumab in severe eosinophilic asthma.
    Eur Respir J. 2025;65:25E6501.
    >> Share

  59. AMEGADZIE JE, Mehareen J, Khakban A, Joshi P, et al
    20-year trends in excess costs of COPD.
    Eur Respir J. 2025;65:2400516.
    >> Share

    December 2024
  60. GUO Y, Donnelly LE
    Identification of an emphysema-specific ATII cell: a step towards understanding impaired lung regeneration in COPD?
    Eur Respir J. 2024;64:2401741.
    >> Share

  61. PIZZICHINI MMM, Pizzichini E
    Is asthma remission an important clinical outcome in asthma management?
    Eur Respir J. 2024;64:2401908.
    >> Share

  62. OKTELIK FB, Benamar M
    Glycerolipids disrupt regulatory T-cells in asthma.
    Eur Respir J. 2024;64:2401386.
    >> Share

  63. BODDULURI S, Nakhmani A, Kizhakke Puliyakote AS, Reinhardt JM, et al
    Airway tapering in COPD.
    Eur Respir J. 2024;64:2400191.
    >> Share

  64. MAURAT E, Raasch K, Leipold AM, Henrot P, et al
    A novel in vitro tubular model to recapitulate features of distal airways: the bronchioid.
    Eur Respir J. 2024;64:2400562.
    >> Share

  65. HERMANN EA, Sun Y, Hoffman EA, Allen NB, et al
    Lung structure and longitudinal change in cardiac structure and function: the MESA COPD Study.
    Eur Respir J. 2024;64:2400820.
    >> Share

  66. WENG C, Zhao Y, Song M, Shao Z, et al
    Mosaic loss of chromosome Y, tobacco smoking and risk of age-related lung diseases: insights from two prospective cohorts.
    Eur Respir J. 2024;64:2400968.
    >> Share

    November 2024
  67. CHAN AHY, De Keyser HH, Horne R, Szefler SJ, et al
    Defining adherence phenotype and endotypes to personalise asthma management.
    Eur Respir J. 2024 Nov 27:2401357. doi: 10.1183/13993003.01357-2024.
    >> Share

  68. GUO R, Wat D, Ho S, Lam M, et al
    Cardiovascular Benefits and Safety Profile of Macrolide Maintenance Therapy in Patients with Bronchiectasis.
    Eur Respir J. 2024 Nov 27:2401574. doi: 10.1183/13993003.01574-2024.
    >> Share

  69. KHALEVA E, Brightling C, Eiwegger T, Altraja A, et al
    Patient-centred composite scores as tools for assesment of response to biological therapy for paediatric and adult severe asthma.
    Eur Respir J. 2024 Nov 7:2400691. doi: 10.1183/13993003.00691-2024.
    >> Share

  70. CRINER GJ, Gayen S, Zantah M, Dominguez Castillo E, et al
    Clinical review of non-invasive ventilation.
    Eur Respir J. 2024;64:2400396.
    >> Share

  71. POLVERINO F, Woodruff PG
    Radiomultiomics: pioneering precision medicine for severe asthma.
    Eur Respir J. 2024;64:2401639.
    >> Share

  72. TIEW PY, Leung JM, Mac Aogain M, Johal P, et al
    Residential exposure to Aspergillus spp. is associated with exacerbations in COPD.
    Eur Respir J. 2024;64:2400907.
    >> Share

    October 2024
  73. CHALMERS JD, Mall MA, Chotirmall SH, O'Donnell AE, et al
    Targeting neutrophil serine proteases in bronchiectasis.
    Eur Respir J. 2024 Oct 28:2401050. doi: 10.1183/13993003.01050-2024.
    >> Share

  74. HAMADA Y, Thomas D, Harvey ES, Stevens S, et al
    Distinct trajectories of treatment response to mepolizumab toward remission in patients with severe eosinophilic asthma.
    Eur Respir J. 2024 Oct 10:2400782. doi: 10.1183/13993003.00782-2024.
    >> Share

  75. KERMANI NZ, Chung KF, Macis G, Santini G, et al
    Radiomultiomics: quantitative CT clusters of severe asthma associated with multi-omics.
    Eur Respir J. 2024 Oct 10:2400207. doi: 10.1183/13993003.00207-2024.
    >> Share

  76. ROJAS-QUINTERO J, Ochsner SA, Lee HS, Cong C, et al
    Skewed adaptive immune responses are involved in AATD emphysema.
    Eur Respir J. 2024 Oct 10:2400839. doi: 10.1183/13993003.00839-2024.
    >> Share

  77. MCSORLEY HJ
    RIPK2 inhibition gets the NOD for asthma.
    Eur Respir J. 2024;64:2401372.
    >> Share

  78. HOEPER MM
    Selexipag: still looking for its place.
    Eur Respir J. 2024;64:2401560.
    >> Share

  79. CABRERA LOPEZ C, Figueira-Goncalves JM
    Previous exacerbations in newly diagnosed COPD patients: do they matter?
    Eur Respir J. 2024;64:2401019.
    >> Share

  80. HALPIN DMG, Healey H, Skinner D, Carter V, et al
    Exacerbation history and blood eosinophil count prior to diagnosis of COPD and risk of subsequent exacerbations.
    Eur Respir J. 2024;64:2302240.
    >> Share

    September 2024
  81. WECHSLER ME, Brusselle G, Virchow JC, Bourdin A, et al
    Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies.
    Eur Respir J. 2024 Sep 26:2400316. doi: 10.1183/13993003.00316-2024.
    >> Share

  82. ZHU Z, Shibata R, Hoffman KL, Cormier J, et al
    Integrated nasopharyngeal airway metagenome and asthma genetic risk endotyping of severe bronchiolitis in infancy and risk of childhood asthma.
    Eur Respir J. 2024 Sep 26:2401130. doi: 10.1183/13993003.01130-2024.
    >> Share

  83. GIBSON PG, McDonald VM
    Integrating hot topics and implementation of treatable traits in asthma.
    Eur Respir J. 2024 Sep 10:2400861. doi: 10.1183/13993003.00861-2024.
    >> Share

  84. CHALMERS JD, Shteinberg M, Mall MA, O'Donnell AE, et al
    Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF(R), a Phase II randomised, double-blind, placebo-controlled, dose-finding study.
    Eur Respir J. 2024 Sep 10:2401551. doi: 10.1183/13993003.01551-2024.
    >> Share

  85. LAHOUSSE L
    Overweight and dysanapsis in childhood asthma.
    Eur Respir J. 2024;64:2401164.
    >> Share

  86. MAKRINIOTI H, Fainardi V, Bonnelykke K, Custovic A, et al
    European Respiratory Society statement on preschool wheezing disorders: updated definitions, knowledge gaps and proposed future research directions.
    Eur Respir J. 2024;64:2400624.
    >> Share

  87. BACKMAN H
    10 pack-years of smoking: not the magic number for COPD risk and prognosis.
    Eur Respir J. 2024;64:2401230.
    >> Share

  88. WENZEL SE
    Allergen challenge, eosinophils and the long road to asthma endotypes.
    Eur Respir J. 2024;64:2401316.
    >> Share

  89. COLAK Y, Lokke A, Marott JL, Lange P, et al
    Low smoking exposure and development and prognosis of COPD over four decades: a population-based cohort study.
    Eur Respir J. 2024;64:2400314.
    >> Share

  90. MIDDLETON PG, Simmonds NJ
    Reversal of cystic bronchiectasis with elexacaftor/tezacaftor/ivacaftor.
    Eur Respir J. 2024;64:2400929.
    >> Share

  91. YILDIRIM AO, Conlon TM, Adcock IM, Gosens R, et al
    COPD-iNET: a call to the lung community for action to combat the global epidemic of COPD.
    Eur Respir J. 2024;64:2400921.
    >> Share

    August 2024
  92. VERSI A, Azim A, Ivan FX, Abdel-Aziz MI, et al
    Host-microbial interactions differ with age of asthma onset.
    Eur Respir J. 2024 Aug 30:2400428. doi: 10.1183/13993003.00428-2024.
    >> Share

  93. SHLOBIN OA, Adir Y, Barbera JA, Cottin V, et al
    Pulmonary hypertension associated with lung diseases.
    Eur Respir J. 2024 Aug 29:2401200. doi: 10.1183/13993003.01200-2024.
    >> Share

  94. AILI A, Wang Y, Shang Y, Zhang L, et al
    LPG 18:0 is a general biomarker of asthma and inhibits the differentiation and function of regulatory T cells.
    Eur Respir J. 2024 Aug 15:2301752. doi: 10.1183/13993003.01752-2023.
    >> Share

  95. HU Y, Hu Q, Ansari M, Riemondy K, et al
    Airway derived emphysema-specific alveolar type II cells exhibit impaired regenerative potential in COPD.
    Eur Respir J. 2024 Aug 15:2302071. doi: 10.1183/13993003.02071-2023.
    >> Share

  96. ABDO M, Pedersen F, Kirsten AM, Trinkmann F, et al
    Association of airway inflammation and smoking status with IL-33 level in sputum of patients with asthma or COPD.
    Eur Respir J. 2024 Aug 15:2400347. doi: 10.1183/13993003.00347-2024.
    >> Share

  97. ALVAREZ-SIMON D, Ait Yahia S, Audousset C, Fanton d'Andon M, et al
    Local Receptor-interacting Protein Kinase 2 inhibition mitigates HDM-induced asthma.
    Eur Respir J. 2024 Aug 8:2302288. doi: 10.1183/13993003.02288-2023.
    >> Share

  98. BLOOM C
    The burden of zoster in asthma: what is left to learn?
    Eur Respir J. 2024;64:2401300.
    >> Share

  99. AL SA'IDI L, Berton DC, Neder JA
    The 2022 ERS/ATS z-score classification to grade airflow obstruction: relationship with exercise outcomes across the spectrum of COPD severity.
    Eur Respir J. 2024;64:2301960.
    >> Share

  100. BROWN JS
    The importance of airway IL-1beta in patients with bronchiectasis.
    Eur Respir J. 2024;64:2400997.
    >> Share

  101. KHURANA S, Georas SN
    Stepping down biologics in asthma: is it time to challenge the status quo?
    Eur Respir J. 2024;64:2401168.
    >> Share

  102. ALIBERTI S, Chalmers JD
    Reply to: Sputum colour matters: haemoptysis in a bronchiectasis registry.
    Eur Respir J. 2024;64:2401390.
    >> Share

  103. YAMAMOTO S, Ishikawa H, Takeda K, Kawashima M, et al
    Sputum colour matters: haemoptysis in a bronchiectasis registry.
    Eur Respir J. 2024;64:2400745.
    >> Share

    July 2024
  104. GAUVREAU GM, Sehmi R, FitzGerald JM, Leigh R, et al
    Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled, trial.
    Eur Respir J. 2024 Jul 26:2400512. doi: 10.1183/13993003.00512-2024.
    >> Share

  105. WILKINSON A, Woodcock A
    High-quality and low-carbon asthma care go hand in hand.
    Eur Respir J. 2024;64:2400638.
    >> Share

  106. SOUMAGNE T, Degano B
    Real world evidence in asthma: what to expect beyond randomised controlled trials?
    Eur Respir J. 2024;64:2400716.
    >> Share

  107. LU J, Wang Z
    Mendelian randomisation supports no evidence of the association between asthma and coronary heart disease in East Asians.
    Eur Respir J. 2024;64:2400628.
    >> Share


  108. "Airway clearance management in people with bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)." A. Spinou, B. Hererro-Cortina, S. Aliberti, et al. Eur Respir J 2024; 63: 2301689.
    Eur Respir J. 2024;64:2351689.
    >> Share

    June 2024
  109. MORTIMER KJ, Cruz AA, Sepulveda-Pachon IT, Jorga A, et al
    Global herpes zoster burden in adults with asthma: a systematic review and meta-analysis.
    Eur Respir J. 2024 Jun 20:2400462. doi: 10.1183/13993003.00462-2024.
    >> Share

  110. STIKKER B, Trap L, Sedaghati-Khayat B, de Bruijn MJW, et al
    Epigenomic partitioning of a polygenic risk score for asthma reveals distinct genetically driven disease pathways.
    Eur Respir J. 2024 Jun 20:2302059. doi: 10.1183/13993003.02059-2023.
    >> Share

  111. SAIKUMAR JAYALATHA AK, Ketelaar ME, Hesse L, Badi YE, et al
    IL-33 induced gene expression in activated Th2 effector cells is dependent on IL-1RL1 haplotype and asthma status.
    Eur Respir J. 2024 Jun 6:2400005. doi: 10.1183/13993003.00005-2024.
    >> Share

  112. VERBANCK S, Eddy RL, McIntosh MJ, Parraga G, et al
    Missing airways, ventilation defects and conductive airway physiology in asthma.
    Eur Respir J. 2024 Jun 6:2400242. doi: 10.1183/13993003.00242-2024.
    >> Share

  113. SOENDERGAARD MB, Bjerrum AS, Rasmussen LM, Lock-Johansson S, et al
    OPTIMAL: Titration of anti-IL5 biologics in severe asthma - An open label randomised controlled trial.
    Eur Respir J. 2024 Jun 6:2400404. doi: 10.1183/13993003.00404-2024.
    >> Share

  114. SPINOU A, Almagro M, Harris B, Boyd J, et al
    Diagnostic delay and access to care in bronchiectasis: data from the EMBARC/ELF patient survey.
    Eur Respir J. 2024 Jun 6:2301504. doi: 10.1183/13993003.01504-2023.
    >> Share

  115. KOVACS G, Humbert M
    Primum non nocere, secundum cavere, tertium sanare: lessons on the management of pulmonary hypertension associated with COPD.
    Eur Respir J. 2024;63:2400765.
    >> Share

  116. CAI J, Vonder M, Du Y, Pelgrim GJ, et al
    Who is at risk of lung nodules on low-dose CT in a Western country? A population-based approach.
    Eur Respir J. 2024;63:2301736.
    >> Share

  117. MCDOWELL PJ, McDowell R, Busby J, Eastwood MC, et al
    Clinical remission with biologic therapies in severe asthma: a matter of definition.
    Eur Respir J. 2024;63:2400160.
    >> Share

  118. BEASLEY R, Noble J, Weatherall M
    The evidence base for ICS/formoterol maintenance and reliever therapy in severe asthma.
    Eur Respir J. 2024;63:2400523.
    >> Share

  119. IMTIAZ A, King J, Holmes S, Gupta A, et al
    ChatGPT versus Bing: a clinician assessment of the accuracy of AI platforms when responding to COPD questions.
    Eur Respir J. 2024;63:2400163.
    >> Share

    May 2024
  120. PEREA L, Bottier M, Cant E, Richardson H, et al
    Airway IL-1beta is related to disease severity and mucociliary function in bronchiectasis.
    Eur Respir J. 2024 May 29:2301966. doi: 10.1183/13993003.01966-2023.
    >> Share

  121. KJELDGAARD JENSEN S, Tingskov Pedersen CE, Fischer-Rasmussen K, Elsner Melgaard M, et al
    Genetic predisposition to high BMI increases risk of early life respiratory infections and episodes of severe wheeze and asthma.
    Eur Respir J. 2024 May 29:2400169. doi: 10.1183/13993003.00169-2024.
    >> Share

  122. NATHAN SD, Argula R, Trivieri MG, Aziz S, et al
    Inhaled Treprostinil in Pulmonary Hypertension Associated with COPD: PERFECT study results.
    Eur Respir J. 2024 May 29:2400172. doi: 10.1183/13993003.00172-2024.
    >> Share

  123. CHOI H, McShane PJ, Aliberti S, Chalmers JD, et al
    Bronchiectasis management in adults: state of the art and future directions.
    Eur Respir J. 2024 May 23:2400518. doi: 10.1183/13993003.00518-2024.
    >> Share

  124. LIU T, Prescott WG, Zhou X
    Advances in Non-Type 2 Asthma in the Severe Cases: from molecular insights to novel treatment strategies.
    Eur Respir J. 2024 May 2:2300826. doi: 10.1183/13993003.00826-2023.
    >> Share

  125. ELBEHAIRY AF, Marshall H, Naish JH, Wild JM, et al
    Advances in COPD imaging using CT and MRI: linkage with lung physiology and clinical outcomes.
    Eur Respir J. 2024;63:2301010.
    >> Share

  126. RAMAKRISHNAN S, Montgomery B, Pavord ID
    Blood eosinophils and lung function loss: from passive prediction to active prevention?
    Eur Respir J. 2024;63:2400812.
    >> Share

  127. BUSH A, Randerath W, Roche N
    As needed ICS/formoterol: not all of Europe is equal.
    Eur Respir J. 2024;63:2400408.
    >> Share

  128. HONG YS, Park HY, Ryu S, Shin SH, et al
    The association of blood eosinophil counts and FEV(1) decline: a cohort study.
    Eur Respir J. 2024;63:2301037.
    >> Share

  129. POLVERINO F, Sin DD
    Type 2 airway inflammation in COPD.
    Eur Respir J. 2024;63:2400150.
    >> Share

    April 2024
  130. SPINOU A, Hererro-Cortina B, Aliberti S, Goeminne PC, et al
    Airway clearance management in people with bronchiectasis: data from the European Bronchiectasis Registry (EMBARC).
    Eur Respir J. 2024 Apr 12:2301689. doi: 10.1183/13993003.01689-2023.
    >> Share

  131. HATTER L, Holliday M, Eathorne A, Bruce P, et al
    The carbon footprint of as-needed budesonide-formoterol in mild asthma: a post hoc analysis.
    Eur Respir J. 2024 Apr 12:2301705. doi: 10.1183/13993003.01705-2023.
    >> Share

  132. JACKSON DJ, Pelaia G, Emmanuel B, Tran TN, et al
    Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme.
    Eur Respir J. 2024 Apr 4:2301521. doi: 10.1183/13993003.01521-2023.
    >> Share

  133. COTTIN V
    Combined pulmonary fibrosis and emphysema syndrome: the age of majority.
    Eur Respir J. 2024;63:2400353.
    >> Share

  134. KRISHNAN JA, Buhl R
    As-needed ICS/formoterol or as-needed SABA in mild asthma?
    Eur Respir J. 2024;63:2302308.
    >> Share

  135. PAPI A, Ferreira DS, Tonia T, Schleich F, et al
    Response from the authors: As-needed ICS/formoterol or as-needed SABA in mild asthma?
    Eur Respir J. 2024;63:2400395.
    >> Share


  136. "Therapeutic improvement of CFTR function and reversibility of bronchiectasis in cystic fibrosis." M.O. Wielputz and M.A. Mall. Eur Respir J 2024; 63: 2400234.
    Eur Respir J. 2024;63:2450234.
    >> Share

  137. TANG RD, Yue JQ, Guan WJ
    Sputum colour as a simplified effective biomarker for clinical assessment of bronchiectasis.
    Eur Respir J. 2024;63:2400152.
    >> Share

  138. STANESCU C, Talarico R, Weichenthal S, Villeneuve PJ, et al
    Early life exposure to pollens and increased risks of childhood asthma: a prospective cohort study in Ontario children.
    Eur Respir J. 2024;63:2301568.
    >> Share

  139. ALIBERTI S, Ringshausen FC, Dhar R, Haworth CS, et al
    Objective sputum colour assessment and clinical outcomes in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC).
    Eur Respir J. 2024;63:2301554.
    >> Share

  140. VARRICCHI G, Brightling CE, Grainge C, Lambrecht BN, et al
    Airway remodelling in asthma and the epithelium: on the edge of a new era.
    Eur Respir J. 2024;63:2301619.
    >> Share

  141. BLOOM CI
    Reply: Asthma and cardiovascular disease: the strength of triangulation.
    Eur Respir J. 2024;63:2400554.
    >> Share

  142. TATTERSALL MC, Gangnon RE, Jarjour NN
    Asthma and cardiovascular disease: embracing disease heterogeneity is required.
    Eur Respir J. 2024;63:2400469.
    >> Share


  143. ERJ Podcast April 2024: Allergic bronchopulmonary aspergillosis.
    Eur Respir J. 2024;63:24E6304.
    >> Share

    March 2024
  144. LIU T, Liu S, Rui X, Cao Y, et al
    Gasdermin B, an asthma-susceptibility gene, promotes MAVS-TBK1 signaling and airway inflammation.
    Eur Respir J. 2024 Mar 21:2301232. doi: 10.1183/13993003.01232-2023.
    >> Share

  145. LUO RG, Wu YF, Lu HW, Weng D, et al
    Th2-skewed peripheral T helper cells drives B cells in allergic bronchopulmonary aspergillosis.
    Eur Respir J. 2024 Mar 21:2400386. doi: 10.1183/13993003.00386-2024.
    >> Share

  146. RUSSELL RJ, Boulet LP, Brightling CE, Pavord ID, et al
    The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma.
    Eur Respir J. 2024 Mar 7:2301397. doi: 10.1183/13993003.01397-2023.
    >> Share

  147. JIN Z, Wang G
    Some future directions for genome-wide association studies of preserved ratio impaired spirometry.
    Eur Respir J. 2024;63:2400142.
    >> Share


  148. "Asthma and incident coronary heart disease: an observational and Mendelian randomisation study." C.A. Valencia-Hernandez, F. Del Greco M, V. Sundaram, et al. Eur Respir J 2023; 62: 2301788.
    Eur Respir J. 2024;63:2351788.
    >> Share


  149. "Aberrant anti-viral response of natural killer cells in severe asthma." J. Devulder, C. Chenivesse, V. Ledroit, et al. Eur Respir J 2020; 55: 1802422.
    Eur Respir J. 2024;63:1852422.
    >> Share

  150. WIELPUTZ MO, Mall MA
    Therapeutic improvement of CFTR function and reversibility of bronchiectasis in cystic fibrosis.
    Eur Respir J. 2024;63:2400234.
    >> Share

  151. BOS S, Murray J, Marchetti M, Cheng GS, et al
    ERS/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-versus-host disease in adults.
    Eur Respir J. 2024;63:2301727.
    >> Share

    February 2024
  152. COHEN R, Shteinberg M
    Unravelling the "frequent exacerbator" phenotype in cystic fibrosis.
    Eur Respir J. 2024;63:2400068.
    >> Share

  153. WANG T, Duan W, Jia X, Huang X, et al
    Associations of combined phenotypic ageing and genetic risk with incidence of chronic respiratory diseases in the UK Biobank: a prospective cohort study.
    Eur Respir J. 2024;63:2301720.
    >> Share

  154. VERLEDEN SE, Lapperre TS, Snoeckx A, Wen W, et al
    Interalveolar pore morphology in (pre-)COPD stages and associations with small airways.
    Eur Respir J. 2024;63:2302263.
    >> Share


  155. ERJ Podcast February 2024: Beetroot juice and cardiovascular risk in COPD.
    Eur Respir J. 2024;63:24E6302.
    >> Share

    August 2023

  156. ERJ Podcast August 2024: Titration of anti-IL-5 biologics in severe asthma.
    Eur Respir J. 2024;64:24E6402.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016